Rexahn Pharmaceuticals, Inc. (RNN) Initiates Phase 2a Clinical Trial Of Archexin® In Patients With Metastatic Renal Cell Carcinoma
1/14/2014 9:51:16 AM
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the initiation of a Phase IIa clinical proof-of-concept trial to study the safety and efficacy of Archexin® in patients with metastatic renal cell carcinoma (RCC). Archexin was previously granted Orphan Drug Designation for the RCC indication.
Help employers find you! Check out all the jobs and post your resume.
comments powered by